DXCM has been the subject of several other research reports. Zacks Investment Research cut DexCom from a hold rating to a strong sell rating in a report on Tuesday, October 4th. BMO Capital Markets assumed coverage on DexCom in a report on Friday, September 16th. They issued an outperform rating and a $112.00 price objective for the company. Morgan Stanley cut DexCom from an overweight rating to an equal weight rating and dropped their price objective for the stock from $87.00 to $66.00 in a report on Tuesday, January 3rd. BTIG Research upgraded DexCom from a neutral rating to a buy rating and set a $92.00 price objective for the company in a report on Monday, October 31st. Finally, Desjardins upgraded DexCom from a hold rating to a buy rating in a report on Friday, September 16th. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $88.67.
Shares of DexCom (NASDAQ:DXCM) traded up 2.67% on Tuesday, hitting $68.83. The company had a trading volume of 1,726,070 shares. The firm’s 50 day moving average price is $64.83 and its 200-day moving average price is $79.31. DexCom has a 52 week low of $47.92 and a 52 week high of $96.38. The stock’s market capitalization is $5.82 billion.
ILLEGAL ACTIVITY WARNING: “DexCom, Inc. (DXCM) Given Buy Rating at Canaccord Genuity” was originally posted by Sports Perspectives and is the propert of of Sports Perspectives. If you are viewing this report on another website, it was stolen and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2017/01/11/dexcom-inc-dxcm-given-buy-rating-at-canaccord-genuity.html.
In other news, EVP Andrew K. Balo sold 4,997 shares of DexCom stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $82.31, for a total value of $411,303.07. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Steven Robert Pacelli sold 10,300 shares of DexCom stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $81.95, for a total value of $844,085.00. The disclosure for this sale can be found here. Company insiders own 2.80% of the company’s stock.
Several large investors have recently modified their holdings of DXCM. BNP Paribas Arbitrage SA boosted its stake in shares of DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock valued at $105,000 after buying an additional 1,162 shares during the period. Bellwether Investment Group LLC purchased a new stake in shares of DexCom during the second quarter valued at about $119,000. Global X Management Co. LLC boosted its stake in shares of DexCom by 118.9% in the third quarter. Global X Management Co. LLC now owns 1,900 shares of the medical device company’s stock valued at $167,000 after buying an additional 1,032 shares during the period. Capstone Asset Management Co. purchased a new stake in shares of DexCom during the third quarter valued at about $205,000. Finally, Profund Advisors LLC purchased a new stake in shares of DexCom during the third quarter valued at about $205,000.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.